(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Savara's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SVRA's revenue for 2026 to be $3,326,246,564, with the lowest SVRA revenue forecast at $1,916,070,117, and the highest SVRA revenue forecast at $4,097,963,421. On average, 2 Wall Street analysts forecast SVRA's revenue for 2027 to be $20,720,554,394, with the lowest SVRA revenue forecast at $11,300,077,960, and the highest SVRA revenue forecast at $30,141,030,828.
In 2028, SVRA is forecast to generate $29,419,436,678 in revenue, with the lowest revenue forecast at $23,438,414,992 and the highest revenue forecast at $35,400,458,364.